In this webinar, Diana Golubeva, Scientist in the Immunology group at STEMCELL Technologies, presents a robust, scalable platform for differentiating human pluripotent stem cells (hPSCs) into functional immune cells to support the development of allogeneic cell therapies. By integrating TeSR™-AOF 3D for xeno-free suspension culture and STEMdiff™ Hematopoietic-EB reagents, the protocol enables efficient generation of CD34⁺ hematopoietic stem and progenitor cells (HSPCs) at high yields. These HSPCs serve as a foundation for downstream differentiation into lymphoid lineages—including natural killer (NK), T, and B cells—using STEMdiff™ and StemSpan™ kits, all optimized for feeder-free workflows and scalable bioreactor formats.

Diana highlights how this 3D system supports robust and reproducible immune cell production, with suspension-derived CD34⁺ cells demonstrating strong potential for NK and T cell generation and cytotoxicity against multiple cancer targets. Additionally, the new STEMdiff™ B Cell Kit enables the generation of CD19⁺ B cells and antibody-secreting cells (ASCs), creating opportunities for applications in immunotherapy and protein replacement. This end-to-end platform offers researchers a powerful, modular solution for generating clinically relevant immune cells at scale, with key benefits for both discovery and translational workflows.

As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.